Pasithea Therapeutics (KTTA) Share-based Compensation (2021 - 2026)
Pasithea Therapeutics (KTTA) posted Share-based Compensation of $721000.0 for Q1 2026, up 716.75% sequentially from $88277.0 in Q4 2025, and up 643.3% YoY from $97000.0 in Q1 2025.
Pasithea Therapeutics (KTTA) Share-based Compensation (2021 - 2026) Analysis & Trends
Pasithea Therapeutics has reported Share-based Compensation for 6 years, with the latest figure at $721000.0 in Q1 2026.
- Quarterly Share-based Compensation rose 643.3% year-over-year to $721000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $721000.0 (up 108.33% YoY) and the FY2025 annual result came in at $860000.0, up 32.64% from the prior year.
- Share-based Compensation advanced to $721000.0 in Q1 2026 per KTTA's latest filing, from $88277.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $721000.0 in Q1 2026 and troughed at -$6943.0 in Q4 2024.
- A 5-year average of $154221.9 and a median of $101480.0 in 2022 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation plunged 286.58% in 2024, then soared 1371.45% in 2025.
- Over 5 years, Share-based Compensation stood at $424672.0 in 2022, then sank by 100.42% to -$1796.0 in 2023, then slumped by 286.58% to -$6943.0 in 2024, then jumped by 1371.45% to $88277.0 in 2025, then surged by 716.75% to $721000.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $721000.0, $88277.0, and $86000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.00 Bn | 132.14 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.24 Bn | 60.06 Bn | 1.37 Bn | - |
| 4 | Moderna | 62.41 Bn | 57.27 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.18 Bn | 27.88 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.93 Bn | 10.54 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - | - |
| 10 | Pasithea Therapeutics | 15.70 Mn | 15.70 Mn | - | 614,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 721,000.00 |
| Mar 31, 2026 | 721,000.00 |
| Dec 31, 2025 | 88,277.00 |
| Dec 31, 2025 | 88,277.00 |
| Sep 30, 2025 | 86,000.00 |
| Sep 30, 2025 | 86,000.00 |
| Jun 30, 2025 | 57,645.00 |
| Jun 30, 2025 | 57,645.00 |
| Mar 31, 2025 | 97,000.00 |
| Mar 31, 2025 | 97,000.00 |
| Dec 31, 2024 | -6,943.00 |
| Dec 31, 2024 | -6,943.00 |
| Sep 30, 2024 | 121,346.00 |
| Sep 30, 2024 | 121,346.00 |
| Jun 30, 2024 | 134,680.00 |
| Jun 30, 2024 | 134,680.00 |
| Mar 31, 2024 | 297,602.00 |
| Mar 31, 2024 | 297,602.00 |
| Dec 31, 2023 | -1,796.00 |
| Dec 31, 2023 | -1,796.00 |